Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia

NCT04150887 is registered in ClinicalTrials.gov with OncoVerity, Inc. as lead sponsor.

NCT NCT04150887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia
Lead sponsor
OncoVerity, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 23, 2019
Completion date
May 15, 2027
Enrollment
61 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute